IPO Archives -

Exscientia’s artificial intelligence-based drug discovery engine is still largely unproven, but that hasn’t stopped the company raking in

AI specialist Exscientia raises $510m in upsized IPO, placing

https://pharmaphorum.com/news/ai-specialist-exscientia-raises-510m-in-upsized-ipo-placing/

News/ News/ Sales and Marketing

Oxford Nanopore makes stellar debut on UK stock market

Phil Taylor financing, Gene Sequencing, genomics, IPO, Oxford Nanopore, UK biotech 0 Comment

Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock

Oxford Nanopore makes stellar debut on UK stock market

https://pharmaphorum.com/news/oxford-nanopore-makes-stellar-debut-on-uk-stock-market/

News/ News/ Oncology

Ambrx tries another IPO as it chases down HER2 rivals

Phil Taylor Ambrx Biopharma, antibody-drug conjugate, AstraZeneca, Enhertu, financing, her2, IPO, Kadcyla, Roche 0 Comment

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock

Ambrx tries another IPO as it chases down HER2 rivals

https://pharmaphorum.com/news/ambrx-tries-another-ipo-as-it-chases-down-her2-rivals/

R&D/ Views & Analysis/ Views and analysis

Arecor heads for London Stock Exchange with drug reformulation strategy

Richard Staines AIM, Arecor, biologics, IPO 0 Comment

Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its

Arecor heads for London Stock Exchange with drug reformulation strategy

https://pharmaphorum.com/views-and-analysis/arecor-heads-for-london-stock-exchange-with-drug-reformulation-strategy/

Stock brokers looking at computer screens, trading online.

News/ News/ R&D

Centessa plans $100m IPO to fund R&D and potential acquisitions

Richard Staines cancer, Centessa, IPO, R&D, rare disease 0 Comment

Centessa has announced plans for a $100m US IPO just weeks after the company launched with $250m in

Centessa plans $100m IPO to fund R&D and potential acquisitions

https://pharmaphorum.com/news/centessa-plans-100m-ipo-to-fund-rd-and-potential-acquisitions/

News/ News/ Oncology

Cancer Research UK spinout Achilles raises $175.5m in IPO

Phil Taylor Achilles Therapeutics, Biotech, cell therapy, immuno-oncology, IPO, Oncology, UK 0 Comment

UK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that

Cancer Research UK spinout Achilles raises $175.5m in IPO

https://pharmaphorum.com/news/cancer-research-uk-spinout-achilles-raises-175-5m-in-ipo/

News/ News/ R&D

Protein misfolding specialist Gain nets $40m from IPO

Phil Taylor computational, digital, drug discovery, Gain Therapeutics, IPO, Protein Misfolding, rare disease 0 Comment

Gain Therapeutics has priced its initial public offering, raising more than $40 million for its computational drug discovery

Protein misfolding specialist Gain nets $40m from IPO

https://pharmaphorum.com/news/protein-misfolding-specialist-gain-nets-40m-from-ipo/

News/ News/ Oncology

Rubius launches $200m IPO to fund red blood cell therapies

Richard Staines acute myeloid leukaemia, cancer, immunology, IPO, solid tumours 0 Comment

Rubius Therapeutics has announced the pricing of its Nasdaq IPO, aiming to raise $200 million towards its novel

Rubius launches $200m IPO to fund red blood cell therapies

https://pharmaphorum.com/news/rubius-launches-200m-ipo-for-red-blood-cell-therapies/

The rise and rise of digital health investment

News/ News/ R&D

UK biotech investment at record levels amid COVID-19

Phil Taylor financing, investment, IPO, UK, UK biotech, venture capital 0 Comment

New figures have confirmed that the UK’s biotech sector received a massive boost from the COVID-19 pandemic last

UK biotech investment at record levels amid COVID-19

https://pharmaphorum.com/news/uk-biotech-investment-at-record-levels-amid-covid-19/

Trending

IPO

Login